All In Biotech

Drug Trial Radar · NCT07110194

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Mar 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.

Conditions

  • CD20-positive Hematological Malignancies

Interventions

  • TQB2825 Injection (Subcutaneous Injection)Drug

    TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak timeTime frame: Up to 4 month
  2. Peak concentration CmaxTime frame: Up to 4 month
  3. Plasma elimination half-life t1/2Time frame: Up to 4 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.